Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Bazedoxifene (Wyeth).

Christian Gruber¹, Doris Gruber

¹Department of Gynecological Endocrinology and Reproductive Medicine, University of Vienna Medical School, A-1090 Vienna, Wahringer Gurtel 18-20, Austria. christian_gruber@chello.at

Current Opinion in Investigational Drugs (London, England : 2000)

|November 13, 2004

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.

British journal of pharmacology·2025

Same author

A community effort in SARS-CoV-2 drug discovery.

Molecular informatics·2023

Same author

Culture of care in animal research - Expanding the 3Rs to include people.

Laboratory animals·2022

Same author

Communication as teaching content of veterinary studies - a joint position paper from the DVG specialist group "communication and didactics" and the GMA veterinary medicine committee.

GMS journal for medical education·2021

Same author

A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening.

iScience·2021

Same author

Simulation of Dynamic and Meta-Dynamic Recrystallization Behavior of Forged Alloy 718 Parts Using a Multi-Class Grain Size Model.

Materials (Basel, Switzerland)·2021

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

Bazedoxifene, a selective estrogen receptor modulator, is being studied for osteoporosis prevention and treatment in postmenopausal women. It is also being evaluated for menopausal symptoms when combined with Premarin.

Area of Science:

Pharmacology
Endocrinology
Women's Health

Background:

Selective estrogen receptor modulators (SERMs) offer tissue-specific effects.
Osteoporosis and menopausal symptoms significantly impact postmenopausal women's health.

Purpose of the Study:

To evaluate bazedoxifene for osteoporosis prevention and treatment.
To assess bazedoxifene in combination with Premarin for menopausal symptom relief.

Main Methods:

Ongoing worldwide phase III clinical trials.
Bazedoxifene administered alone and in combination with Premarin.

Main Results:

Phase III trials were ongoing as of March and June 2004.
Data on efficacy and safety were still being collected.

Related Experiment Videos

Conclusions:

Bazedoxifene shows potential as a therapeutic agent for postmenopausal women.
Further results from phase III trials are anticipated to confirm its clinical utility.